Abstract
To expand the donor pool, allogeneic stem cell transplantation (SCT) using HLA 2-3 antigen-mismatched (haploidentical) related donors has been studied. To date, there are a few reports describing nonmyeloablative stem cell transplantation (NST) from HLA-haploidentical donors. We recently showed that a nonmyeloablative regimen consisting of fludarabine, busulfan, and ATG was sufficiently immunosuppressive to achieve donor type engraftment in transplantation from HLA-haploidentical donors who had 1 antigen-mismatch in the GVH direction and 2-3 antigen-mismatches in the HVG direction (Leukemia, 2003).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
